

School of Medicine, Cardiff University 6th Floor, Neuadd Meirionnydd Heath Park, Cardiff CF14 4YS

Ysgol Meddygaeth, Prifysgol Caerdydd 6ed Llawr, Neuadd Meirionnydd, Parc y Mynydd Bychan, Caerdydd CF14 4YS

Telephone/Ffon 029 2068 7500

Facsimile/Ffacs 029 2068 7501

www.wctu.org.uk

1st June 2012

Dr Corinne Scott Administrator MREC for Wales 6th Floor, Churchill House 17 Churchill Way Cardiff CF10 2TW

Dear Dr Scott

Re 08/MRE09/29 AML 17: A Programme of Development for the Treatment of Younger Patients with Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome

On behalf of the Chief Investigator Prof Alan Burnett, I am writing to inform you of a non-substantial amendment to the above study. There has recently been a change in the pharmacovigilance details that are listed in the trial management group and also a typographical error on section 20.5.3 where the dosage of Mylotarg should read 3mg/m². Therefore we have amended the protocol with the updated information, and to save any confusion, have updated the version to 7.2 dated June 2012

Yours Sincerely

Alison Jenkins AML17 Trial Manager

Alson Sentis







